- Home
- LGMK vs WINT Comparison
LGMK vs WINT Comparison
Compare LGMK & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- WINT
- Stock Information
- Founded
- LGMK 2011
- WINT 1992
- Country
- LGMK United States
- WINT United States
- Employees
- LGMK N/A
- WINT N/A
- Industry
- LGMK Industrial Specialties
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGMK Health Care
- WINT Health Care
- Exchange
- LGMK Nasdaq
- WINT Nasdaq
- Market Cap
- LGMK 1.3M
- WINT 1.5M
- IPO Year
- LGMK N/A
- WINT 1995
- Fundamental
- Price
- LGMK $0.02
- WINT $1.39
- Analyst Decision
- LGMK
- WINT Hold
- Analyst Count
- LGMK 0
- WINT 1
- Target Price
- LGMK N/A
- WINT $350.00
- AVG Volume (30 Days)
- LGMK 36.8M
- WINT 7.7M
- Earning Date
- LGMK 05-14-2025
- WINT 04-15-2025
- Dividend Yield
- LGMK N/A
- WINT N/A
- EPS Growth
- LGMK N/A
- WINT N/A
- EPS
- LGMK N/A
- WINT N/A
- Revenue
- LGMK $9,901,987.00
- WINT N/A
- Revenue This Year
- LGMK $1.54
- WINT N/A
- Revenue Next Year
- LGMK N/A
- WINT N/A
- P/E Ratio
- LGMK N/A
- WINT N/A
- Revenue Growth
- LGMK 4.43
- WINT N/A
- 52 Week Low
- LGMK $0.02
- WINT $1.10
- 52 Week High
- LGMK $25.38
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- LGMK 11.89
- WINT 30.13
- Support Level
- LGMK $0.02
- WINT $1.10
- Resistance Level
- LGMK $0.11
- WINT $2.17
- Average True Range (ATR)
- LGMK 0.02
- WINT 0.35
- MACD
- LGMK 0.02
- WINT 0.20
- Stochastic Oscillator
- LGMK 1.05
- WINT 12.18
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.